Autophagy inhibition facilitates erlotinib cytotoxicity in lung cancer cells through modulation of endoplasmic reticulum stress

ZHONGLIANG WANG1, TINGTING DU2, XIAORONG DONG1, ZHENYU LI1, GANG WU1 and RUIGUANG ZHANG1

1Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; 2Department of Endocrinology, Wuhan Medical and Health Center for Women and Children, Wuhan, Hubei, P.R. China

Received January 27, 2016; Accepted March 4, 2016

DOI: 10.3892/ijo.2016.3468

Abstract. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have revolutionized the treatment for non-small cell lung cancer patients, but acquired resistance limit the efficiency of this treatment. As a homeostatic cellular recycling mechanism, autophagy has been proposed to participate in the EGFR-TKI resistance. However, the role of autophagy in lung cancer treatment and the underlying mechanisms have not been clarified. In this study, we found the sensitivity to erlotinib, a well-used EGFR-TKI, was correlated with basal autophagy level. Erlotinib was able to induce autophagy not only in TKI-sensitive, but also TKI-resistant cancer cells. Inhibition of autophagy significantly enhanced cytotoxicity of erlotinib in TKI-resistant cancer cells via modulation of endoplasmic reticulum (ER) stress induced apoptosis. In this process, CCAAT/enhancer binding protein (CHOP) acted as an executioner. Downregulation of CHOP with siRNA blocked the autophagy inhibition and erlotinib co-treatment induced apoptosis and prevented cancer cells from this co-treatment-induced cell death. Our findings suggest that autophagy inhibition overcomes erlotinib resistance through modulation of ER stress mediated apoptosis.

Introduction

Non-small-cell lung cancer (NSCLC) is still the leading cause for cancer related mortality worldwide (1,2). Treatment of EGFR-mutant NSCLC patients with specific tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib, has led to remarkable tumor shrinkage and improvement in progression-free survival and quality of life compared with the standard chemotherapy (3-5). However, not all patients respond to TKI treatment, and patients who initially benefited from the TKI treatment inevitably developed drug resistance (6,7). The resistance mechanisms to TKI treatment can be grouped into four categories: mutation of EGFR to a drug-resistance state, for example, T790M mutation; activation of a bypass pathway, such as MET amplification; impairment of a pathway that is essential for TKI-induced apoptosis; and histologic transformation to small cell lung cancer or epithelial-mesenchymal transition (8). Apart from these clues, accumulating evidence indicate that macroautophagy (hereafter autophagy) plays a vital role in the resistance to TKI.

Autophagy is a lysosomal degradative pathway characterized by the formation of double-membrane autophagic vesicles, which engulf portions of the cytosol, damaged organelles, protein aggregates and bacteria. In virtually all cells, autophagy occurs at basal levels to maintain homeostatic balance by updating proteins and organelles (9). Autophagy is upregulated when cells are under unfavorable environments, such as starvation, hypoxia, and drug exposure, to help cells survive in adverse conditions.

Cancer cells have increased metabolic demands due to high levels of cellular proliferation and cellular stress, which activates autophagy to maintain energy balance and to prevent cell death (10). Theoretically, autophagy may be a strategy to confer not only unfavorable environments but also chemicals exposure. Many cancer therapeutics, including TKIs, were reported to activate pro-survival autophagy and blockage of autophagy facilitates cell death (11-14). However, so far, the mechanisms underlying the synergistic effect of EGFR-TKI and autophagy inhibition remains unclear.

The endoplasmic reticulum (ER) is an organelle involved in protein folding and assembly, lipid and sterol biosynthesis, and free calcium storage. ER stress is caused when accumulation of unfolded and misfolded proteins exceed the capacity of the ER process. Upon ER stress, protein kinase RNA (PKR)-like ER kinase (PERK) is activated following dissociation from the ER chaperone GRP78. Activated PERK transiently inhibits protein synthesis by phosphorylating eukaryotic initiation factor 2α (eIF2α). Activation of PERK can also lead to the induction of CCAAT/enhancer binding protein homologous protein (CHOP), which switches the ER stress response from proadaptive to proapoptotic signaling (15-17). Given inhibition
of autophagy would cause accumulation of damaged proteins and excessive accumulation of misfolded proteins would induce ER stress, we reasoned that there may be a link between autophagy inhibition and ER stress induced apoptosis.

In this study, we tested our hypothesis by a combination of western blotting, transmission electron microscopy, and fluorescent microscopy to detect autophagy in several types of cancer cells after erlotinib treatment. We also explored the mechanisms underlying the synergistic effect of autophagy inhibition and erlotinib. Our findings suggest that autophagy acts as a cell protect factor and contributes to the EGFR-TKI resistance. The combination of autophagy inhibition and erlotinib may be a promising route to enhance EGFR-TKI sensitivity and overcome EGFR-TKI resistance.

Materials and methods

Reagents and antibodies. The chemicals used were erlotinib (Selleck), chloroquine (CQ, Sigma), and 3-methyladenine (3-MA, Sigma). Erlotinib was dissolved in dimethylsulfoxide (DMSO), while CQ and 3-MA were dissolved in cells culture medium. The primary antibodies were antibodies against LC-3 (1:1,000, Novus, #NB100-2220), beclin-1 (1:1,000, Cell Signaling Technology, #3495), caspase 3 (1:500, ProteinTech, #19677-1-AP), cleaved-caspase 3 (1:500, Cell Signaling Technology, #9664), chop (1:1,000, Cell Signaling Technology, #2895), p-EIF2α (1:1,000, Cell Signaling Technology, #3398), EIF2α (1:1,000, Cell Signaling Technology, #5324), EGFR (1:1,000, Cell Signaling Technology, #4267) and GAPDH (1:2,000, Cell Signaling Technology, #5174).

Cell culture. The human NSCLC cell lines HCC827 (adenocarcinoma), A549 (adenocarcinoma), H460 (large cell carcinoma) and H1975 (adenocarcinoma) were obtained from Cell Bank (Chinese Academy of Sciences) and maintained in suggested complete medium. HCC827 has a mutation in the EGFR tyrosine kinase domain (E746-A750 deletion). H1975 has two mutations in the EGFR tyrosine kinase domain (L858R and T790M). While A549 and H460 are EGFR wild-type cells. To establish an EGFR-TKI-resistant cell line, HCC827 cells were cultured in medium containing escalating concentrations of erlotinib for 6 months to select cells which could grow in micromolar concentrations of erlotinib. The selected cells were confirmed erlotinib-resistant, and named HCC827-R.

Cell proliferation. The cytotoxicity of chemicals against cancer cells were determined with CCK8 tests. Cells were seeded in 96-well plates at a concentration of 1,500-2,000 cells per well, allowed to attach overnight, and treated with various concentrations of chemicals. After 72-h incubation, 10 µl of CCK8 (Boster, China) was added into each well for another 1-h incubation. Then, the cell optical density (OD) was measured at an absorbance wavelength of 450 nm.

Clonogenic assay. Cells were seeded in 6-well plates at a concentration of 1,000 cells per well, allowed to attach overnight, and treated with 10 µM CQ, 0.1 µM erlotinib, 1 µM erlotinib, alone or in combination. Culture medium and chemicals were replaced every 72 h. After 10-14 days, cells were fixed with methanol and stained with 1% crystal violet. Colonies were counted with ImageJ software.

Western blotting. After chemical treatment, cells were lysed in a lysis buffer containing protease and phosphatase inhibitors. Equal amounts of protein were separated by SDS-PAGE and transferred to PVDF membrane (Millipore, Billerica, MA, USA). After blocking with 5% non-fat milk, the membranes were then incubated overnight at 4°C with primary antibodies. Then, after washing with TBST, the membranes were incubated with corresponding secondary antibodies conjugated with horseradish peroxidase, developed with ECL solution, and exposed onto Hyperfilm (OptiCam600; UVP, USA).

cDNA and siRNA transfection. The GFP-tagged LC3 cDNA expression construct was kindly provided by Professor Jinghua Ren (Union Hospital, Wuhan, China) and transfected with Lipofectamine 2000 (Invitrogen). The CHOP-siRNA and non-specific control of siRNA were from Ribobio Technology (Guangzhou, China) and the targeted sequence of CHOP-siRNA was GGCTCAAGCAGGAATCGA. Cells were transfected with siRNA using Interferin (Plosplus) according to the manufacturer's instructions and incubated 24 h prior to further treatments.

Apoptosis assay. Apoptosis events were measured using FITC Annexin V Apoptosis Detection kit (BD) that quantitatively measures Annexin V or PI (propidium iodide)-positive cells. Western blot analyses were used to detect the protein level of cleaved caspase 3 after various treatments.

Transmission electron microscopy. Transmission electron microscopy was performed as previously described (18). In brief, H1975 cells were treated with erlotinib (1 µM) for 48 h, washed 3 times with PBS, and fixed with glutaraldehyde overnight. After washing with PBS, cells were fixed in 1% OsO4 and embedded in polybed resin. The ultrathin sections were doubly stained with uranyl acetate and lead citrate and analyzed by transmission electron microscopy (Hitachi, Japan).

Quantification and statistics. Differences between groups were compared using the Student's t-test or two-way ANOVA followed by the Bonferroni test. The criterion for statistical significance was P<0.05.

Results

Autophagy involves EGFR-TKI sensitivity. With CCK8 tests, we examined the sensitivity of HCC827, A549, H460, H1975, and HCC827-R cells to erlotinib. HCC827 cells, with a mutation in the EGFR tyrosine kinase domain (E746-A750 deletion), was the most sensitive to erlotinib. In contrast, HCC827-R cells showed significant resistance to erlotinib. A549 and H460 cells, both of EGFR wild-type, were relatively resistant to erlotinib. H1975 cells, with two mutations in the EGFR tyrosine kinase domain (L858R and T790M), showed further resistance to erlotinib than A549 or H460 cells (Fig. 1A and B). In western blotting results, HCC827 cells showed abundant basal EGFR expression, while the basal EGFR
expression of A549, H460 and HCC827-R cells was moderate. H1975 cells showed only slight EGFR expression. We tested the basal autophagy level by measuring the conversion of the LC3/Atg8 from the cytoplasmic form LC3-I, to the autophagic form LC3-II. The results showed that HCC827-R cells expressed considerable level of LC3-II, indicating an active basal autophagy activity. H1975 cells also showed easily detectable amounts of conversion from LC3-I to LC3-II, while the other three cells showed little conversion (Fig. 1C). In line with the expression of LC3-II, HCC827, A549, H460, and H1975 cells showed increasing protein level of beclin-1, which was negatively correlated with the cell sensitivity to erlotinib. However, HCC827-R cells showed slight beclin-1 expression, similarly to HCC827 cells. Given that autophagy is an inducible process under survival stress and the active autophagy activity of HCC827-R and H1975 was generated in a well-cultured environment, just like the other three cell lines, we reasoned that the high basal autophagy levels of HCC827-R and H1975 were not stress-induced, but an intrinsic character and involved in their resistance to erlotinib.

Autophagy is induced in cancer cells after erlotinib treatment. Autophagy was induced under treatment of erlotinib in three cell lines, HCC827, A549, and H1975. With HCC827 cells, 0.1 µM of erlotinib induced marked autophagy just 1 h after exposure and lasted for >48 h. Of note, after 4 h of erlotinib exposure, HCC827 cells showed less conversion of LC3 compared with that of 1-h exposure, but then the conversion of LC3 turned to increase from 4 to 48 h persistently. With A549 cells, 1 µM of erlotinib induced a time-dependent accumulation of autophagy, with the highest level achieved at 24 h. Similar with A549, H1975 cells also showed a time-dependent increase of autophagy under the treatment of erlotinib (1 µM) (Fig. 2A). We also measured the punctate fluorescence after...
erlotinib treatment in the cells transfected with a GFP-tagged LC3 construct. In all three cell lines, erlotinib induced more punctate fluorescence than did the control cells, which showed only slight fluorescence (Fig. 3C). This result was further confirmed with transmission electron microscopy, which revealed autophagosomes in H1975 cells after 48-h erlotinib treatment, whereas autophagosomes were scarce in untreated cells (Fig. 2B). Together, these findings suggest that erlotinib treatment induces autophagy in both EGFR-TKI-sensitive and -resistant cancer cells.

3-MA and CQ abates erlotinib-induced autophagy. As a classic autophagy inhibitor, 3-MA was tested for the ability to abate erlotinib-induced autophagy. With western blotting, 3-MA was able to diminish the conversion from LC3-I to LC3-II in HCC827, A549, and H1975 cells. The combination of 3-MA and erlotinib markedly decreased the erlotinib-induced conversion from LC3-I to LC3-II, nearly to the same level with 3-MA single treatment (Fig. 3A). This result was further confirmed by measuring the punctate fluorescence in the cells transfected with a GFP-tagged LC3 construct.

**Figure 3.** (A) HCC827, A549, and H1975 cells were treated with erlotinib (0.1 µM for HCC827, 1 µM for A549 and H1975), 3-MA (5 mM), or a combination of both for 48 h. Western blotting showed that treatment with 3-MA reversed erlotinib-induced increase of LC3-II in all three cell lines. (B) HCC827, A549, and H1975 cells were treated erlotinib (0.1 µM for HCC827, 1 µM for A549 and H1975), chloroquine (CQ, 10 µM), or a combination of both for 48 h. In all three cell lines, western blotting showed that CQ treatment significantly increased the LC3-II level, while the combination of CQ and erlotinib induced a further accumulation of LC3-II as compared with CQ single treatment. (C) HCC827, A549, and H1975 cells were transfected with a GFP-LC3 construct. In all the three cell lines, photographs from fluorescence microscopy showed that 3-MA reversed the erlotinib-induced punctate fluorescence increase.
In all three cell lines, 3-MA significantly downregulated the erlotinib-induced LC3-GFP protein accumulation (Fig. 3C). We also used CQ, an autophagy-lysosomal inhibitor, to block erlotinib-induced autophagy. While 3-MA is able to inhibit autophagosome formation, CQ functions by blocking the degradation of autophagosomes and thereby induces accumulation of LC3-II. In this experiment, treatment of CQ induced abundant accumulation of LC3-II in all three cell lines. The combination of CQ and erlotinib showed still further LC3-II accumulation than CQ alone, indicating that CQ blocked the degradation of erlotinib-induced autophagosomes (Fig. 3B). Moreover, this result illustrates that the erlotinib-induced LC3-II accumulation was a reflection of increased autophagy flux, rather than dysfunction of lysosomes.

**Combination with autophagy inhibition enhances erlotinib-induced cytotoxicity.** As autophagy might be involved in the resistance of H1975 cells to erlotinib, we tested the synergistic effect of autophagy inhibition and EGFR-TKI by combining 3-MA with erlotinib. With CCK8 tests, 3-MA and erlotinib co-treatment showed significant synergistic cytotoxicity to H1975 cells while 3-MA single treatment showed only slight influence (Fig. 4C). The combination of CQ and erlotinib showed still further LC3-II accumulation than CQ alone, indicating that CQ blocked the degradation of erlotinib-induced autophagosomes (Fig. 3B). Moreover, this result illustrates that the erlotinib-induced LC3-II accumulation was a reflection of increased autophagy flux, rather than dysfunction of lysosomes.

**Combination of autophagy inhibition and erlotinib induces ER stress and apoptosis.** We tested whether combination of erlotinib and inhibition of autophagy with CQ would induce apoptosis in EGFR-TKI-resistant cells. To this aim, H1975 was treated with CQ, erlotinib, alone or in combination for 48 h, and then measured for apoptosis with flow cytometry by quantitatively measuring Annexin V and PI. The results showed CQ induced statistically significant induction of apoptosis, but erlotinib did not. The combination of CQ and erlotinib also induced apoptosis, and this effect was significantly greater than apoptosis seen with CQ single treatment (Fig. 6A). Consistent with the flow cytometry results, western blot analyses revealed
Figure 5. CQ alone or in combination with erlotinib caused nearly complete inhibition of colony formation of NSCLC cell lines. HCC827, A549, and H1975 cells were seeded in 6-well plates and treated with CQ (10 µM), erlotinib (0.1 and 1 µM) alone, or in combination for 10-14 days before being stained (A-C) and the number of colonies was quantified (D). Data are means ± SEM of three independent experiments. **P<0.01, ***P<0.001.

Figure 6. Combination of CQ and erlotinib induced apoptosis through modulation of ER stress. (A) H1975 cells were treated with erlotinib (1 µM), CQ (10 µM), or a combination of both for 48 h. Apoptosis was measured with Annexin V and PI double staining followed by flow cytometry analysis. (B) H1975 cells were treated as in (A) above. Western blotting showed that CQ alone, or in combination with erlotinib, induced cleavage of caspase 3 and upregulation of p-eIF2α and CHOP. (C) H1975 cells were transiently transfected with siRNA against CHOP or control siRNA 24 h before exposed to co-treatment of CQ and erlotinib or no treatment for 48 h. Western blotting showed that siRNA targeting CHOP abolished CQ and erlotinib co-treatment induced upregulation of CHOP and cleavage of caspase 3, but not in control siRNA treated cells. (D) Compared with control siRNA, siRNA targeting CHOP protected H1975 cells from the cytotoxicity of CQ or CQ combination with erlotinib. Data are means ± SEM of three independent experiments. *P<0.05, **P<0.01.
that CQ markedly induced the activation of caspase 3, a critical executioner of apoptosis, which was further enhanced by combination of CQ and erlotinib (Fig. 6B).

The impact of autophagy inhibition and erlotinib on triggering ER stress was analysed by measuring its well-documented markers, CHOP and the phosphorylated form of the initiation factor 2-α (p-eIF2α). CHOP is an ER-stress associated proapoptotic marker, and eIF2α is a translation initiation factor phosphorylated by protein kinase RNA-like endoplasmic reticulum kinase (PERK) in response to ER stress. The protein levels of p-eIF2α and CQ increased in H1975 cells after treatment with CQ for 48 h, whereas the 48-h treatment of erlotinib showed no change. By contrast, co-administration of CQ and erlotinib induced a more significant increase of p-eIF2α and CHOP compared with CQ single treatment (Fig. 6B). These data suggest that CQ with or without erlotinib treatment could induce apoptosis and trigger ER stress.

**CHOP knockdown counteracts the cytotoxicity and apoptosis induced by co-treatment of CQ and erlotinib.** To gain further insight into the role of ER stress in CQ and erlotinib co-treatment induced cytotoxicity, the effects of knockdown of CHOP was tested. At 24 h after CHOP siRNA transfection, H1975 cells was exposed to CQ, erlotinib, or the combination of both chemicals for additional 48 h for western blot analyses or 72 h for CCK8 tests. As a result, knockdown of CHOP blocked the CQ-erlotinib co-treatment induced CHOP upregulation. Also, the cleavage of caspase 3 induced by CQ-erlotinib co-treatment was significantly diminished, indicating blockage of apoptosis caused by CQ-erlotinib co-treatment (Fig. 6C). In CCK8 tests, knockdown of CHOP significantly counteracted the cytotoxicity caused by CQ or CQ-erlotinib co-treatment, while the effect of erlotinib single treatment was not obviously affected (Fig. 6D).

**Discussion**

In this study, we found that erlotinib induced autophagy in three lung cancer cell lines, HCC827, A549, and H1975 by detecting conversion from LC3-I to LC3-II with western blotting. The GFP-LC3 construct and transmission electron microscopy were used to further confirm the autolysosome formation after erlotinib exposure. Two kinds of autophagy inhibitors, 3-MA and CQ, were used to ablate the induction of autophagy under exposure of erlotinib. Synergistic effect between erlotinib and 3-MA/CQ were found in all three cell lines, with CQ single treatment presenting much more cytotoxicity than 3-MA, indicating different mechanisms for blocking autophagy may associate with their distinct cytotoxicity. Co-treatment of CQ and erlotinib induced ER stress in H1975 cells, which evoked apoptosis through modulation of ER stress. Inhibition of CHOP upregulation alleviated apoptosis and counteracted cytotoxicity caused by CQ or CQ-erlotinib co-administration.

**EGFR-EKI induces autophagy.** Accumulating studies have reported that anticancer therapies, including radiotherapy, chemotherapy and targeted therapies, could induce autophagy in different tumor cell lines (19-22). Though the correlation between anticancer therapies and autophagy has been proposed, the role of autophagy in cancer treatment is complex. On the one hand, the role of autophagy is pro-survival and contributes to therapy resistance through removal of damaged cell components and proteins to help cancer cells survive under stress. On the other hand, autophagy is pro-death and contributes to therapy effect by enhancing induction of apoptosis or mediating ‘autophagic cell death’. One theory to explain this double-faced role of autophagy in cancer treatment is that there is a checkpoint in therapy induction of autophagy. As a balance keeper, modest autophagy induction could eliminate damage and recycle energy to promote cancer cells survival. While excessive autophagy may induce vital protein or organ-elle lysis, triggering apoptosis or autophagic cell death, known as the second programmed cell death.

**EGFR-TKIs,** was reported to induce marked autophagy in sensitive cancer cells, like HCC827 and PC-9 (14,18,22). In EGFR-TKI-resistant cancer cells, most authors presented that EGFR-TKI was able to induce autophagy, but Li *et al* reported that EGFR-TKI failed to induce autophagy in resistant cells (23). Apart from targeting EGFR, other TKIs, such as imatinib (targeting BCRABL, KIT, and PDGFR), dasatinib (targeting BCRABL, KIT, and SRC), and sorafenib (a multi-tyrosine-kinase inhibitor), could induce autophagy in distinct tumor cell lines as well (24-26). Furthermore, the anti-EGFR antibody cetuximab was reported to induce autophagy through inhibiting the class I PI3K/Akt/mTOR pathway (13). In this study, we found that erlotinib, a well-used EGFR-TKI, elicited a rapid and robust induction of autophagy in HCC827, and caused a relatively slow but persistent induction of autophagy in A549 and H1975 cells, as demonstrated by the increased conversion of LC3. We also found that EGFR-TKI resistance was positively correlated with baseline autophagy level. As compared with the parental HCC827 cells, HCC827-R cells showed significant resistance to erlotinib and much more conversion of LC3. Consistently, A549, H460, and H1975 cells showed increasing conversion of LC3 and exaggerating resistance to erlotinib. In line with this point, Guo *et al* observed that patients with low LC3 expression had a higher objective response rates in advanced colorectal cancer patients treated with cetuximab-containing chemotherapy, indicating that autophagy may reduce cetuximab efficacy in patients with colorectal cancer (27).

**Autophagy and EGFR-TKI resistance.** EGFR-TKI acquired resistance is the major failure in treatment of NSCLC, in which half of resistance can be attributed to EGFR T790M mutation (3). However, inhibition of signaling molecules downstream of EGFR did not enhance the sensitivity of NSCLC cells with EGFR T790M mutation to EGFR-TKIs, indicating that there may be another pathway mediating EGFR-TKI resistance (2,28). Several studies demonstrated that autophagy inhibition acted synergistically with EGFR-TKIs to induce lung cancer cells death (18,22,29). For example, Zou *et al* (18) reported that erlotinib, at a clinically relevant concentration (2 µM) induced autophagy in NSCLC cells with wild-type EGFR and inhibition of autophagy with CQ enhanced erlotinib cytotoxicity *in vitro* and *in vivo*. In this study, we confirmed the synergistic effect of autophagy inhibition and erlotinib with 3-MA and CQ, two distinct inhibitors of autophagy, in three NSCLC cell lines with different types of EGFR mutation.
ER stress, apoptosis and autophagy. ER responds to ER stress through translational attenuation, enhancement of protein folding ability, and degradation of unfolded proteins by a quality-control system. However, when the stress exceeds the ability of ER to process, apoptotic signals are elicited (37-39). CHOP plays an important role in ER stress-induced apoptosis as the fact that CHOP−/− mice exhibit reduced apoptosis in response to ER stress (40). A link between autophagy and ER stress has been substantiated by the finding that the PERK-eIF2α-ChOP pathway is essential for autophagy induction under ER stress, in which CHOP was able to transcriptionally regulate more than a dozen ATG genes (41,42). On the contrary, elicitation of ER stress demonstrated by increased Ire1α activity was observed in ATG-knockout mice, indicating dysregulated autophagy may also trigger ER stress as a feedback mechanism (43,44). In this study, we found that autophagy inhibition by CQ elicited a slight induction of ER stress, demonstrated by increased eIF2α phosphorylation. Combination of CQ and erlotinib further increased eIF2α phosphorylation, which induced apoptosis through upregulation of CHOP. This autophagy inhibition-induced ER stress offered a further validation for the ER stress-autophagy feedback paradigm and a new interpretation for the synergistic effect of autophagy inhibition and erlotinib.

In conclusion, the role of autophagy in cancer biology and cancer treatment is complex, and related studies have shown consistent, but also contradictory, conclusions. In this study, we confirmed the ability of erlotinib to induce autophagy in not only EGFR-TKI-sensitive but also EGFR-TKI-resistant cancer cells. Inhibition of autophagy acts synergistically with erlotinib to overcome erlotinib resistance through modulation of ER stress induced apoptosis, in which CHOP acts as a key effector molecule. Together, autophagy is elicited as a cytoprotective process when cancer cells are facing erlotinib exposure, and inhibition of autophagy may represent a promising therapeutic strategy to overcome erlotinib resistance in NSCLC.

Acknowledgements
This study was supported by grants from the National Natural Science Foundation of China (no. 81302020).

References


